Rheumatoid Arthritis – Pipeline Review, H1 2012 by GlobalMarketsDirect

VIEWS: 12 PAGES: 348

More Info
									          Rheumatoid Arthritis – Pipeline Review, H1 2012


                                                                                          Reference Code: GMDHC1731IDB
                                                                                           Publication Date: February 2012




Rheumatoid Arthritis – Pipeline Review, H1 2012                                            GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                             Page(1)
Rheumatoid Arthritis – Pipeline Review, H1 2012




Table of Contents
Table of Contents ............................................................................................................................................................................... 2
    List of Tables ............................................................................................................................................................................... 10
    List of Figures .............................................................................................................................................................................. 16
Introduction....................................................................................................................................................................................... 17
    Global Markets Direct Report Coverage ...................................................................................................................................... 17
Rheumatoid Arthritis Overview ......................................................................................................................................................... 18
Therapeutics Development............................................................................................................................................................... 19
    An Overview of Pipeline Products for Rheumatoid Arthritis ......................................................................................................... 19
Rheumatoid Arthritis Therapeutics under Development by Companies ........................................................................................... 21
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes............................................................................. 36
Late Stage Products ......................................................................................................................................................................... 39
    Comparative Analysis .................................................................................................................................................................. 39
Mid Clinical Stage Products.............................................................................................................................................................. 40
    Comparative Analysis .................................................................................................................................................................. 40
Early Clinical Stage Products ........................................................................................................................................................... 41
    Comparative Analysis .................................................................................................................................................................. 41
Discovery and Pre-Clinical Stage Products ...................................................................................................................................... 42
    Comparative Analysis .................................................................................................................................................................. 42
Rheumatoid Arthritis Therapeutics – Products under Development by Companies ......................................................................... 43
Rheumatoid Arthritis Therapeutics – Products under Investigation by Universities/Institutes........................................................... 62
Companies Involved in Rheumatoid Arthritis Therapeutics Development ........................................................................................ 64
    Bristol-Myers Squibb Company ................................................................................................................................................... 64
    Johnson & Johnson ..................................................................................................................................................................... 65
    Boehringer Ingelheim GmbH ....................................................................................................................................................... 66
    F. Hoffmann-La Roche Ltd. ......................................................................................................................................................... 67
    Biogen Idec Inc. ........................................................................................................................................................................... 68
    Amgen Inc. .................................................................................................................................................................................. 69
    AstraZeneca PLC ........................................................................................................................................................................ 70
    Eli Lilly and Company .................................................................................................................................................................. 71
    GlaxoSmithKline plc .................................................................................................................................................................... 72
    Genentech, Inc. ........................................................................................................................................................................... 73
    Inovio Biomedical Corporation ..................................................................................................................................................... 74
    MedImmune LLC ......................................................................................................................................................................... 75
    Isis Pharmaceuticals, Inc. ............................................................................................................................................................ 76
    Biotest AG ................................................................................................................................................................................... 77
    Merck & Co., Inc. ......................................................................................................................................................................... 78
    Santen Pharmaceutical Co., Ltd. ................................................................................................................................................. 79
    Ablynx .......................................................................................................................................................................................... 80
    Micromet, Inc. .............................................................................................................................................................................. 81
    Novo Nordisk A/S ........................................................................................................................................................................ 82
    Plexxikon Inc. .............................................................................................................................................................................. 83
    BioLineRx, Ltd. ............................................................................................................................................................................ 84



Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                             GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                    Page(2)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    arGentis Pharmaceuticals, LLC ................................................................................................................................................... 85
    MediGene AG .............................................................................................................................................................................. 86
    Celltrion, Inc................................................................................................................................................................................. 87
    TiGenix NV .................................................................................................................................................................................. 88
    Pacira Pharmaceuticals, Inc. ....................................................................................................................................................... 89
    Novartis AG ................................................................................................................................................................................. 90
    Astellas Pharma Inc..................................................................................................................................................................... 91
    Biocon Limited ............................................................................................................................................................................. 92
    Daewoong Pharmaceutical Co., Ltd. ........................................................................................................................................... 93
    Dong-A Pharmaceutical Co., Ltd. ................................................................................................................................................ 94
    Glenmark Pharmaceuticals Ltd.................................................................................................................................................... 95
    Maxygen, Inc. .............................................................................................................................................................................. 96
    Mitsubishi Tanabe Pharma Corporation ...................................................................................................................................... 97
    Pfizer Inc...................................................................................................................................................................................... 98
    Rigel Pharmaceuticals, Inc. ......................................................................................................................................................... 99
    Santarus, Inc. ............................................................................................................................................................................ 100
    Teva Pharmaceutical Industries Limited .................................................................................................................................... 101
    Toyama Chemical Co. Ltd ......................................................................................................................................................... 102
    Vertex Pharmaceuticals Incorporated........................................................................................................................................ 103
    Zydus Cadila Healthcare Limited ............................................................................................................................................... 104
    Genmab A/S .............................................................................................................................................................................. 105
    novosom AG .............................................................................................................................................................................. 106
    CEL-SCI Corporation................................................................................................................................................................. 107
    Celgene Corporation ................................................................................................................................................................. 108
    Onyx Pharmaceuticals, Inc. ....................................................................................................................................................... 109
    Incyte Corporation ..................................................................................................................................................................... 110
    Vernalis plc ................................................................................................................................................................................ 111
    Merck KGaA .............................................................................................................................................................................. 112
    Bone Medical Limited ................................................................................................................................................................ 113
    4SC AG ..................................................................................................................................................................................... 114
    3SBio Inc. .................................................................................................................................................................................. 115
    Addex Pharmaceuticals ............................................................................................................................................................. 116
    EntreMed, Inc. ........................................................................................................................................................................... 117
    Evotec Aktiengesellschaft.......................................................................................................................................................... 118
    Genesis Research and Development Corporation Ltd. ............................................................................................................. 119
    GW Pharmaceuticals plc ........................................................................................................................................................... 120
    Hollis-Eden Pharmaceuticals, Inc. ............................................................................................................................................. 121
    IMMUNOMEDICS, INC ............................................................................................................................................................. 122
    Can-Fite BioPharma Ltd. ........................................................................................................................................................... 123
    Idera Pharmaceuticals, Inc. ....................................................................................................................................................... 124
    Karo Bio..................................................................................................................................................................................... 125
    Almirall, S.A. .............................................................................................................................................................................. 126
    Lupin Limited ............................................................................................................................................................................. 127
    Medivir AB ................................................................................................................................................................................. 128


Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                             GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                   Page(3)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    PROLOR Biotech, Inc................................................................................................................................................................ 129
    Novogen Limited........................................................................................................................................................................ 130
    Nutra Pharma Corporation ........................................................................................................................................................ 131
    Compugen Ltd. .......................................................................................................................................................................... 132
    Lexicon Pharmaceuticals, Inc. ................................................................................................................................................... 133
    Accentia Biopharmaceuticals, Inc. ............................................................................................................................................. 134
    Portola Pharmaceuticals, Inc. .................................................................................................................................................... 135
    Chelsea Therapeutics, Inc. ........................................................................................................................................................ 136
    CombinatoRx, Incorporated ....................................................................................................................................................... 137
    Yuhan Corporation .................................................................................................................................................................... 138
    Zenotech Laboratories Limited .................................................................................................................................................. 139
    Regeneron Pharmaceuticals, Inc............................................................................................................................................... 140
    Unigene Laboratories, Inc. ........................................................................................................................................................ 141
    Pharmacyclics, Inc..................................................................................................................................................................... 142
    Protalix BioTherapeutics, Inc. .................................................................................................................................................... 143
    Tolerx, Inc. ................................................................................................................................................................................. 144
    Antisoma plc .............................................................................................................................................................................. 145
    MorphoSys AG .......................................................................................................................................................................... 146
    Boryung Pharmaceutical Co., Ltd. ............................................................................................................................................. 147
    Hanall Pharmaceutical Co., Ltd. ................................................................................................................................................ 148
    LG Life Sciences, Ltd ............................................................................................................................................................... 149
    AnGes MG, Inc. ......................................................................................................................................................................... 150
    Biotie Therapies Corp. ............................................................................................................................................................... 151
    Transition Therapeutics Inc. ...................................................................................................................................................... 152
    LTT Bio-Pharma Co., Ltd........................................................................................................................................................... 153
    Galapagos NV ........................................................................................................................................................................... 154
    Synta Pharmaceuticals Corp. .................................................................................................................................................... 155
    CrystalGenomics, Inc. ............................................................................................................................................................... 156
    Sareum Holdings plc ................................................................................................................................................................. 157
    Protalex, Inc............................................................................................................................................................................... 158
    Proximagen Neuroscience plc. .................................................................................................................................................. 159
    Newron Pharmaceuticals S.p.A. ................................................................................................................................................ 160
    Simcere Pharmaceutical Group ................................................................................................................................................. 161
    Piramal Life Sciences Limited.................................................................................................................................................... 162
    Morphotek, Inc. .......................................................................................................................................................................... 163
    Chroma Therapeutics Ltd. ......................................................................................................................................................... 164
    Advinus Therapeutics Pvt. Ltd. .................................................................................................................................................. 165
    Affimed Therapeutics AG .......................................................................................................................................................... 166
    Ambit Biosciences Corporation.................................................................................................................................................. 167
    AnaMar Medical AB ................................................................................................................................................................... 168
    Viron Therapeutics, Inc.............................................................................................................................................................. 169
    Immupharma Plc ....................................................................................................................................................................... 170
    Palau Pharma S.A ..................................................................................................................................................................... 171
    Philogen S.p.A. .......................................................................................................................................................................... 172


Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                            GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                  Page(4)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    Probiodrug AG ........................................................................................................................................................................... 173
    Acceleron Pharma, Inc. ............................................................................................................................................................. 174
    Phenex Pharmaceuticals AG ..................................................................................................................................................... 175
    Neovacs SA ............................................................................................................................................................................... 176
    MIKA Pharma GmbH ................................................................................................................................................................. 177
    CREABILIS Therapeutics S.r.l. .................................................................................................................................................. 178
    Artielle ImmunoTherapeutics, Inc. ............................................................................................................................................. 179
    Aquinox Pharmaceuticals Inc. ................................................................................................................................................... 180
    Amura Holdings Ltd. .................................................................................................................................................................. 181
    JADO Technologies GmbH. ...................................................................................................................................................... 182
    AnaptysBio, Inc.......................................................................................................................................................................... 183
    IMMD Inc. .................................................................................................................................................................................. 184
    Circassia Holdings Ltd. .............................................................................................................................................................. 185
    Funxional Therapeutics Ltd ....................................................................................................................................................... 186
    Oxagen Limited ......................................................................................................................................................................... 187
    Catabasis Pharmaceuticals, Inc. ............................................................................................................................................... 188
    Recoly N.V................................................................................................................................................................................. 189
    Opsona Therapeutics Ltd. ......................................................................................................................................................... 190
    Asahi Kasei Pharma .................................................................................................................................................................. 191
    Vaccinex, Inc. ............................................................................................................................................................................ 192
    Syntrix Biosystems, Inc. ............................................................................................................................................................ 193
    Peptimmune, Inc........................................................................................................................................................................ 194
    S*BIO Pte Ltd ............................................................................................................................................................................ 195
    Deciphera Pharmaceuticals, LLC .............................................................................................................................................. 196
    Indus Biotech Private Limited .................................................................................................................................................... 197
    NovImmune SA ......................................................................................................................................................................... 198
    Txcell SA ................................................................................................................................................................................... 199
    Theraclone Sciences, Inc. ......................................................................................................................................................... 200
    Theracos, Inc. ............................................................................................................................................................................ 201
    TcL Pharma SAS ....................................................................................................................................................................... 202
    Versartis, Inc.............................................................................................................................................................................. 203
    Cardax Pharmaceuticals, Inc. .................................................................................................................................................... 204
    Virobay Inc................................................................................................................................................................................. 205
    Myriad Pharmaceuticals, Inc...................................................................................................................................................... 206
    Inimex Pharmaceuticals, Inc. ..................................................................................................................................................... 207
    Karus Therapeutics Ltd ............................................................................................................................................................. 208
    Logical Therapeutics, Inc........................................................................................................................................................... 209
    Omeros Corporation .................................................................................................................................................................. 210
    Xencor, Inc. ............................................................................................................................................................................... 211
    BioStar Pharmaceuticals, Inc..................................................................................................................................................... 212
    Cornerstone Therapeutics Inc. .................................................................................................................................................. 213
    Acetylon Pharmaceuticals, Inc................................................................................................................................................... 214
    Trillium Therapeutics Inc. .......................................................................................................................................................... 215
    SBI Biotech Co., Ltd. ................................................................................................................................................................. 216


Rheumatoid Arthritis – Pipeline Review, H1 2012                                                                                           GMDHC1731IDB / Pub February 2012
© Global Markets Direct. This report is a licensed product and is not to be photocopied                                                                                                 Page(5)
Rheumatoid Arthritis – Pipeline Review, H1 2012




    CBio Limited .............................................................................................................................................................................. 217
    VentiRx Pharmaceuticals, Inc. ................................................................................................................................................... 218
    KaloBios Pharmaceuticals, Inc. ................................................................................................................................................. 219
    AB Science ................................................................................................................................................................................ 220
    Resolvyx Pharmaceuticals, Inc .................................................................................................................................................. 221
    OncoImmune, Inc. ..................................................................................................................................................................... 222
    Avesthagen Limited ................................................................................................................................................................... 223
    Nuon Therapeutics, Inc. ............................................................................................................................................................ 224
    KAHR medical Ltd. ........................................................................................................................
								
To top